StemoniX is a biotechnology company that develops ready-to-use, human iPSC-derived 3D culture systems, including neural (microBrain®) and cardiac (microHeart®) organoids, for high-throughput drug discovery, disease modeling, and toxicology research.[1][2] These physiologically relevant platforms serve pharmaceutical scientists and researchers by enabling consistent, reproducible assays that improve translatability from preclinical to human outcomes, while easing workflows through simplified implementation and a Discovery as a Service outsourcing model for custom screening and cell supply.[1][2] The company addresses key challenges in drug development, such as poor predictivity of traditional 2D models, helping bring promising medicines to patients more efficiently.[1][2]
StemoniX emerged as a Johnson & Johnson J-Labs startup in La Jolla, California, with roots in advancing microOrgan platform technology for preclinical applications.[2] Co-founder and CEO Ping Yeh led the company's growth, highlighted by the 2019 opening of a state-of-the-art R&D facility in La Jolla to focus on disease modeling, drug discovery, and collaborations like one with the NIH's National Center for Advancing Translational Sciences on Rett Syndrome models.[2] Early milestones included demonstrating the platform's versatility for electrophysiologically active neural and cardiac cells, building traction in high-throughput screening.[2] By 2023, StemoniX expanded operations to Minnesota, but its assets, including the microBrain™ technology for neurological disease R&D (e.g., Parkinson's, epilepsy, Rett syndrome), were acquired by AxoSim, combining it with platforms like NerveSim® and BrainSim® for enhanced organoid-based drug discovery.[3]
StemoniX rides the wave of organoid and iPSC technologies transforming drug discovery by replacing animal models with human-relevant 3D systems, improving R&D success rates for brain disorders and toxicology where traditional methods fail.[1][3] Timing aligns with rising demand for predictive preclinical tools amid high drug failure rates (over 90% in neurology), fueled by advances in stem cell tech and regulatory pushes for humanized assays.[2][3] Market forces like pharma's shift to outsourced, efficient platforms favor StemoniX's model, influencing the ecosystem through tech transfer—its acquisition by AxoSim consolidates leading organoid platforms (microBrain™, NerveSim®, BrainSim®), accelerating innovation in neurological R&D and enabling faster lead candidate selection.[3]
Post-2023 acquisition, StemoniX's microOrgan tech now powers AxoSim's expanded capabilities in live biomimetic models, positioning it to dominate organoid-based R&D for hard-to-treat diseases like epilepsy, Parkinson's, and MS.[3] Trends like AI-driven screening and expanded iPSC libraries will amplify its momentum, potentially driving partnerships with big pharma for neurotoxicology and personalized medicine. As organoids become standard, its influence could evolve from niche supplier to core enabler of "humanized" pipelines, ensuring medicines work correctly the first time—echoing its founding mission to revolutionize discovery.[1][2][3]
StemoniX has raised $17.0M in total across 2 funding rounds.
StemoniX's investors include Positive Sum VC.
StemoniX has raised $17.0M across 2 funding rounds. Most recently, it raised $14.0M Series B in February 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2019 | $14.0M Series B | Positive Sum VC | |
| Oct 1, 2016 | $3.0M Seed | Positive Sum VC |
